Suma Krishnan, President, R&D, 10% Owner at Krystal Biotech, Inc. (KRYS), sold 25,000 shares at $354.54 ($9.0M) on 2026-09-04, disclosed to the SEC on 2026-09-04.
Scheduled sale ($9.0M) by President, R&D, 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $354.54 | 520 | $184K | 2.1% |
| 2 | $355.57 | 2,006 | $713K | 7.9% |
| 3 | $356.37 | 3,267 | $1.2M | 13.0% |
| 4 | $357.57 | 3,962 | $1.4M | 15.8% |
| 5 | $358.42 | 3,180 | $1.1M | 12.7% |
| 6 | $359.39 | 3,392 |
| $1.2M |
| 13.6% |
| 7 | $360.47 | 2,320 | $836K | 9.3% |
| 8 | $361.61 | 1,242 | $449K | 5.0% |
| 9 | $362.65 | 1,992 | $722K | 8.0% |
| 10 | $363.34 | 565 | $205K | 2.3% |
| 11 | $364.48 | 1,329 | $484K | 5.4% |
| 12 | $365.41 | 826 | $302K | 3.4% |
| 13 | $366.56 | 399 | $146K | 1.6% |
| Total | $359.32 avg | 25,000 | $9.0M | 100% |
| Filing → |
| KRYS | SELL | 2025-12-05 | $20.9M | — | Filing → |
| KRYS | SELL | 2025-07-16 | $10.1M | — | Filing → |
| KRYS | SELL | 2025-07-11 | $4.0M | — | Filing → |